JP2023518976A5 - - Google Patents

Info

Publication number
JP2023518976A5
JP2023518976A5 JP2022558088A JP2022558088A JP2023518976A5 JP 2023518976 A5 JP2023518976 A5 JP 2023518976A5 JP 2022558088 A JP2022558088 A JP 2022558088A JP 2022558088 A JP2022558088 A JP 2022558088A JP 2023518976 A5 JP2023518976 A5 JP 2023518976A5
Authority
JP
Japan
Prior art keywords
composition according
nanoemulsion
nanoemulsion composition
virus
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518976A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019103 external-priority patent/WO2021194672A1/en
Publication of JP2023518976A publication Critical patent/JP2023518976A/ja
Publication of JP2023518976A5 publication Critical patent/JP2023518976A5/ja
Pending legal-status Critical Current

Links

JP2022558088A 2020-03-23 2021-02-22 Rnaを送達するための組成物および方法 Pending JP2023518976A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062993307P 2020-03-23 2020-03-23
US62/993,307 2020-03-23
US202063054754P 2020-07-21 2020-07-21
US63/054,754 2020-07-21
PCT/US2021/019103 WO2021194672A1 (en) 2020-03-23 2021-02-22 Compositions and methods for delivery of rna

Publications (2)

Publication Number Publication Date
JP2023518976A JP2023518976A (ja) 2023-05-09
JP2023518976A5 true JP2023518976A5 (cg-RX-API-DMAC7.html) 2024-02-08

Family

ID=74885039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558088A Pending JP2023518976A (ja) 2020-03-23 2021-02-22 Rnaを送達するための組成物および方法

Country Status (10)

Country Link
US (15) US20220110881A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126021A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023518976A (cg-RX-API-DMAC7.html)
KR (1) KR20220156933A (cg-RX-API-DMAC7.html)
CN (1) CN115551548A (cg-RX-API-DMAC7.html)
AU (1) AU2021241355A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019124A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172489A1 (cg-RX-API-DMAC7.html)
GB (2) GB2605538B (cg-RX-API-DMAC7.html)
WO (1) WO2021194672A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Sars-cov-2 rnaワクチン組成物および使用方法
CA3232562A1 (en) * 2021-09-22 2023-03-30 Malcolm S. Duthie Nucleic acid sensor agonist compositions and uses thereof
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
EP4460326A4 (en) * 2022-01-07 2026-03-11 Hdt Bio Corp COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIVALENT IMMUNE RESPONSES
US11648332B1 (en) * 2022-04-22 2023-05-16 Innovative Technologies Universal air purification system
CN116942610A (zh) * 2022-04-29 2023-10-27 北京祥瑞生物制品股份有限公司 一种核酸药物递送系统及其制备方法
WO2023228116A1 (en) * 2022-05-24 2023-11-30 Access To Advanced Health Institute Intranasal administration of thermostable rna vaccines
WO2024020453A2 (en) * 2022-07-20 2024-01-25 Hdt Bio Corp. Immune system modulators and uses thereof
WO2024031051A1 (en) 2022-08-05 2024-02-08 Life Technologies Corporation Lipids for nucleic acid delivery
WO2024148169A1 (en) * 2023-01-06 2024-07-11 Hdt Bio Corp. Nanoparticle complexes for enhanced safety
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
EP4694867A2 (en) * 2023-04-13 2026-02-18 Massachusetts Institute of Technology Lipid nanoparticles for delivery of agents
WO2025027116A1 (en) 2023-08-01 2025-02-06 Institut Curie Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
WO2025231068A1 (en) * 2024-04-30 2025-11-06 The Regents Of The University Of Michigan Compositions and methods for enhancing systemic and mucosal immune responses

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
WO2001021810A1 (en) 1999-09-17 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU2002305914A1 (en) 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
WO2004055216A2 (en) 2002-12-13 2004-07-01 Fox Chase Cancer Center Replication of hepatitis c virus in non-hepatic epithelial and mouse hepatic cells
CA2539490A1 (en) 2003-09-18 2005-03-24 Genmab A/S Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
TWI388344B (zh) 2005-08-23 2013-03-11 Celsion Corp 儲存奈米微粒調合物之方法
WO2007098267A2 (en) 2006-02-27 2007-08-30 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008124647A2 (en) 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
US9446150B2 (en) * 2007-10-09 2016-09-20 Washington University Particles for imaging
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2401365B1 (en) 2009-02-24 2016-04-27 The Scripps Research Institute Reengineering mrna primary structure for enhanced protein production
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
US8722853B2 (en) 2010-06-10 2014-05-13 University Of Washington Through Its Center For Commercialization Methods and systems for adenovirus interaction with desmoglein 2 (DSG2)
US9555136B2 (en) 2010-06-21 2017-01-31 University Of Washington Through Its Center For Commercialization Coated magnetic nanoparticles
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9101669B2 (en) 2012-01-31 2015-08-11 Postech Academy-Industry Foundation Self-assembed conjugate and use thereof
EP4299138A3 (en) 2012-08-03 2024-08-14 Access to Advanced Health Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
US20160000886A1 (en) 2013-02-22 2016-01-07 President And Fellows Of Harvard College Nanostructured active therapeutic vehicles and uses thereof
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
RU2546249C2 (ru) 2013-08-07 2015-04-10 Силезиа Груп Пте. Лтд. Композиция для усиления экспрессии трансгена в эукариотических клетках и способ увеличения продукции целевого белка, кодируемого трансгеном
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
SG11201705820UA (en) 2015-01-16 2017-08-30 Nat Inst Advanced Ind Science & Tech Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CN106176599A (zh) 2015-05-06 2016-12-07 江苏天士力帝益药业有限公司 一种卡巴他赛脂肪乳注射剂及其制备方法
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
CN106445676B (zh) * 2015-08-05 2019-10-22 杭州海康威视系统技术有限公司 一种分布式数据计算的任务分配方法和任务分配装置
EP3352785A1 (en) * 2015-09-23 2018-08-01 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
KR20180082457A (ko) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
MA46023A (fr) 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
DE102017206254B4 (de) 2016-04-13 2024-07-11 Dialog Semiconductor (Uk) Limited DC-DC-Umwandlung für Mehrzellen-Batterien
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
EP3458088A2 (en) 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
EP3463300A1 (en) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018022957A1 (en) * 2016-07-29 2018-02-01 Tarveda Therapeutics, Inc. T cell binding conjugates and methods of use
KR20180025701A (ko) 2016-09-01 2018-03-09 (주)아모레퍼시픽 특정 siRNA을 포함하는 멜라닌 증진용 조성물
WO2018053294A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
WO2018081638A1 (en) 2016-10-27 2018-05-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2018147710A1 (ko) 2017-02-13 2018-08-16 단디바이오사이언스 주식회사 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도
AU2018285694B2 (en) * 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
US12065649B2 (en) 2018-01-09 2024-08-20 Vanderbilt University Pattern recognition receptor agonist prodrugs and methods of use thereof
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
AU2019215191B2 (en) 2018-02-02 2025-08-14 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
US20190382450A1 (en) 2018-06-18 2019-12-19 University Of Maryland, College Park Newcastle disease virus-based vectored vaccine
KR20210104835A (ko) 2018-12-19 2021-08-25 누클레인, 엘엘씨 분자 진단을 위한 장치 및 방법
WO2020146690A1 (en) 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of rna replicons
US11406699B2 (en) 2019-03-22 2022-08-09 George Mason University Alphavirus and compositions, methods, and kits related thereto
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
GB201908729D0 (en) 2019-06-18 2019-07-31 Imp College Innovations Ltd RNA construct
EP4004037A1 (en) 2019-07-26 2022-06-01 Vanderbilt University Human monoclonal antibodies to enterovirus d68
US11716044B2 (en) * 2019-09-02 2023-08-01 Toshiba Mitsubishi-Electric Industrial Systems Corporation Power conversion device and electric motor drive system
US11679163B2 (en) * 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021194672A1 (en) * 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
JP2022550454A (ja) 2019-10-02 2022-12-01 ユニバーシティ オブ ワシントン B型肝炎ウイルス感染の治療のための組成物及び方法
WO2021072112A1 (en) 2019-10-09 2021-04-15 Hdt Bio Corp. Detection of desmoglein-2 in cancers of epithelial origin
AU2020367786A1 (en) 2019-10-14 2022-05-26 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
KR102754152B1 (ko) * 2019-10-18 2025-01-14 현대모비스 주식회사 사이드 에어백 장치
BR112022016054A2 (pt) 2020-02-14 2022-10-11 Altimmune Inc Composições imunogênicas para coronavírus e usos das mesmas
WO2021178416A1 (en) 2020-03-02 2021-09-10 Heat Biologics, Inc. Immune-mediated coronavirus treatments
US11478543B1 (en) 2020-03-06 2022-10-25 Thomas Jefferson University Coronavirus disease (COVID-19) vaccine
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
TWI891771B (zh) 2020-04-17 2025-08-01 美商Vlp醫療股份有限公司 冠狀病毒疫苗
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
WO2022217079A1 (en) 2021-04-08 2022-10-13 Georgia State University Research Foundation, Inc. Graphene oxide nanoparticles and methods of use for stimulating immune responses
IN202121031414A (cg-RX-API-DMAC7.html) 2021-07-13 2023-01-13
IN202121038492A (cg-RX-API-DMAC7.html) 2021-08-25 2023-03-03
AU2022358446A1 (en) 2021-09-22 2024-04-18 Hdt Bio Corp. Compositions and methods for enhanced protein production
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
WO2023049363A1 (en) 2021-09-24 2023-03-30 Amgen Inc. Sotorasib and afatinib for treating cancer comprising a kras g12c mutation

Similar Documents

Publication Publication Date Title
US11318213B2 (en) Compositions and methods for delivery of RNA
Couvreur et al. Nanotechnology: Intelligent Design to Treat Complex Disease: Couvreur and Vauthier
EP4404977A2 (en) Nucleic acid sensor agonist compositions and uses thereof
US11679163B2 (en) Compositions and methods for delivery of RNA
WO2023133500A2 (en) Compositions and methods for multivalent immune responses
EP4442257A1 (en) Nanoparticle compositions comprising one or more variants of poly(d,l-lactic-co-glycolic acid)
HK40086331A (en) Compositions and methods for delivery of rna
Al-Deen On the Delivery of Blood Stage Malaria DNA Vaccine Using Magnetic Nanoparticles
Nawwab Al-Deen On the delivery of blood stage malaria DNA vaccine using magnetic nanoparticles